Home Equity First Majestic Silver And NASDAQ TEST STOCK Among The List Of The...

First Majestic Silver And NASDAQ TEST STOCK Among The List Of The Most Active Winners And Losers Of Wednesday’s US Session

January 19, 2022

404

(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are First Majestic Silver, Hecla Mining, and Unilever.

Rank	Financial Asset	Price	Change	Updated (EST)
1	First Majestic Silver (AG)	11.77	11.67%	2022-01-19 13:38:10
2	Hecla Mining (HL)	5.75	11.24%	2022-01-19 13:42:23
3	Unilever (UL)	50.51	8.75%	2022-01-19 13:47:40
4	Randgold (GOLD)	20.17	8.67%	2022-01-19 16:26:52
5	Kinross Gold (KGC)	5.93	8.21%	2022-01-19 13:43:08
6	Yamana Gold (AUY)	4.42	7.42%	2022-01-19 13:38:35
7	BP Prudhoe Bay Royalty Trust (BPT)	6.19	7.25%	2022-01-19 11:15:06
8	Merrimack Pharmaceuticals (MACK)	4.88	7.25%	2022-01-19 16:12:39
9	XP (XP)	29.06	6.45%	2022-01-19 16:03:50
10	Take-Two Interactive Software (TTWO)	163.36	6.05%	2022-01-19 16:14:40

The three most active and biggest losers today are NASDAQ TEST STOCK, NeuroMetrix, and Full House Resorts.

Rank	Financial Asset	Price	Change	Updated (EST)
1	NASDAQ TEST STOCK (ZWZZT)	15.00	-25%	2022-01-18 19:46:11
2	NeuroMetrix (NURO)	5.44	-14.6%	2022-01-19 13:36:12
3	Full House Resorts (FLL)	8.83	-9.06%	2022-01-19 16:11:17
4	Zentalis Pharmaceuticals (ZNTL)	61.46	-9%	2022-01-18 19:41:13
5	Y-mAbs Therapeutics (YMAB)	11.06	-8.75%	2022-01-18 19:08:06
6	Super Micro Computer (SMCI)	42.15	-8.71%	2022-01-19 16:14:11
7	Plug Power (PLUG)	20.99	-8.06%	2022-01-19 16:13:35
8	Ameresco (AMRC)	52.69	-7.77%	2022-01-19 01:43:12
9	U.S. Bancorp (USB)	57.37	-7.75%	2022-01-19 16:24:54
10	Concord Medical Services Holdings Limited ADS (CCM)	1.77	-7.33%	2022-01-19 15:49:14

Most Active Winners today

1. First Majestic Silver (AG) – 11.67%

NYSE ended the session with First Majestic Silver jumping 11.67% to $11.77 on Wednesday while NYSE dropped 0.63% to $16,844.15.

Volume

Today’s last reported volume for First Majestic Silver is 7353650 which is 69.27% above its average volume of 4344250.

First Majestic Silver’s last close was $10.54, 56.1% under its 52-week high of $24.01.

The company’s growth estimates for the present quarter is a negative 50% and positive 200% for the next.

First Majestic Silver’s Revenue

Year-on-year quarterly revenue growth grew by 342%, now sitting on 497.55M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

First Majestic Silver’s stock is considered to be overbought (>=80).

First Majestic Silver’s Stock Yearly Top and Bottom Value

First Majestic Silver’s stock is valued at $11.77 at 16:32 EST, way under its 52-week high of $24.01 and way higher than its 52-week low of $9.62.

First Majestic Silver’s Moving Average

First Majestic Silver’s value is under its 50-day moving average of $12.32 and way below its 200-day moving average of $14.09.

More news about First Majestic Silver.

2. Hecla Mining (HL) – 11.24%

NYSE ended the session with Hecla Mining rising 11.24% to $5.75 on Wednesday, following the last session’s upward trend. NYSE dropped 0.63% to $16,844.15, after three sequential sessions in a row of losses, on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for Hecla Mining is 10711700 which is 59.86% above its average volume of 6700280.

Hecla Mining’s last close was $5.17, 45.23% below its 52-week high of $9.44.

Hecla Mining’s Sales

Hecla Mining’s sales growth is 1.4% for the ongoing quarter and 6.8% for the next. The company’s growth estimates for the present quarter and the next is 33.3% and 100%, respectively.

Hecla Mining’s Revenue

Year-on-year quarterly revenue growth declined by 3.1%, now sitting on 811.28M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Hecla Mining’s stock is considered to be overbought (>=80).

Hecla Mining’s Stock Yearly Top and Bottom Value

Hecla Mining’s stock is valued at $5.75 at 16:32 EST, way below its 52-week high of $9.44 and way above its 52-week low of $4.65.

Hecla Mining’s Moving Average

Hecla Mining’s value is higher than its 50-day moving average of $5.69 and way below its 200-day moving average of $6.71.

More news about Hecla Mining.

3. Unilever (UL) – 8.75%

NYSE ended the session with Unilever rising 8.75% to $50.51 on Wednesday while NYSE fell 0.63% to $16,844.15.

Volume

Today’s last reported volume for Unilever is 17902600 which is 451.47% above its average volume of 3246340.

Unilever’s last close was $46.45, 26.33% under its 52-week high of $63.05.

News about Unilever today

Unilever rules out raising offer for glaxo consumer brands. According to today’s article on Bloomberg Quint, "The outcome is a serious blow to Unilever Chief Executive Officer Alan Jope, who earlier this week announced a revamp of the business. "

Unilever’s Revenue

Year-on-year quarterly revenue growth grew by 0.3%, now sitting on 50.8B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Unilever’s stock is considered to be oversold (<=20).

Unilever’s Stock Yearly Top and Bottom Value

Unilever’s stock is valued at $50.51 at 16:32 EST, under its 52-week low of $51.98.

Unilever’s Moving Average

Unilever’s worth is below its 50-day moving average of $53.48 and way under its 200-day moving average of $57.01.

Previous days news about Unilever

Unilever pursues glaxo and Pfizer consumer health venture. According to The New York Times on Monday, 17 January, "That shift simplified operations – and made it easier for Unilever to buy companies using its own stock.", "Monday’s announcement was effectively a signal of intent that Unilever was willing to pursue one of the costliest takeover fights in the consumer health business in recent years. "
Unilever sets out ambition to expand in health products. According to The Wall Street Journal on Monday, 17 January, "The strategic update Monday came days after Unilever said it had approached GlaxoSmithKline PLC and Pfizer Inc. about buying their consumer-healthcare joint venture, GSK Consumer Healthcare. "
Unilever faces investor hurdle as shadow of mega deals looms. According to Bloomberg Quint on Tuesday, 18 January, "Some investors have already communicated their view by selling Unilever shares for the second day since news broke of its 50 billion-pound ($68 billion) approach to Glaxo, an offer the drugmaker rejected.", "Glaxo’s management will no doubt take note of the lukewarm shareholder response at Unilever as the drugmaker weighs the merits of an uncertain merger versus a spinoff of the business. "
Glaxosmithkline shares soar after unilever bid for consumer health unit. According to MarketWatch on Monday, 17 January, "Shares of GlaxoSmithKline surged on Monday, while Unilever stock tumbled following a failed $68 billion bid by the latter to acquire the pharmaceutical giant’s consumer healthcare arm.", "Driving the FTSE 100 higher and at the top of the Stoxx Europe 600’s gainer’s list, was GlaxoSmithKline , up 5% after saying Saturday that it has rejected an unsolicited £50 billion ($68.4 billion) Unilever offer for the unit behind painkiller Advil and Sensodyne toothpaste that it jointly owns with Pfizer . "

More news about Unilever.

4. Randgold (GOLD) – 8.67%

NASDAQ ended the session with Randgold rising 8.67% to $20.17 on Wednesday while NASDAQ fell 1.15% to $14,340.25.

Volume

Today’s last reported volume for Randgold is 35461200 which is 108.34% above its average volume of 17020700.

Randgold’s last close was $18.56, 26.84% under its 52-week high of $25.37.

Randgold’s Sales

Randgold’s sales growth is a negative 9.7% for the present quarter and a decline by 0.6% for the next. The company’s growth estimates for the present quarter and the next is a negative 22% and a negative 2.9%, respectively.

Randgold’s Revenue

Year-on-year quarterly revenue growth declined by 5.3%, now sitting on 12.67B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Randgold’s stock is considered to be overbought (>=80).

Randgold’s Stock Yearly Top and Bottom Value

Randgold’s stock is valued at $20.17 at 16:32 EST, way under its 52-week high of $25.37 and way higher than its 52-week low of $17.56.

Randgold’s Moving Average

Randgold’s value is above its 50-day moving average of $19.16 and below its 200-day moving average of $20.63.

More news about Randgold.

5. Kinross Gold (KGC) – 8.21%

NYSE ended the session with Kinross Gold jumping 8.21% to $5.93 on Wednesday while NYSE slid 0.63% to $16,844.15.

Volume

Today’s last reported volume for Kinross Gold is 19690500 which is 27.73% above its average volume of 15415100.

Kinross Gold’s last close was $5.48, 34.29% under its 52-week high of $8.34.

Kinross Gold’s Sales

Kinross Gold’s sales growth is a negative 17.6% for the ongoing quarter and a decline by 17.4% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 72% and a negative 70.4%, respectively.

Kinross Gold’s Revenue

Year-on-year quarterly revenue growth declined by 0.6%, now sitting on 4.31B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Kinross Gold’s stock is considered to be overbought (>=80).

Kinross Gold’s Stock Yearly Top and Bottom Value

Kinross Gold’s stock is valued at $5.93 at 16:32 EST, way under its 52-week high of $8.34 and way above its 52-week low of $5.18.

Kinross Gold’s Moving Average

Kinross Gold’s value is above its 50-day moving average of $5.88 and under its 200-day moving average of $6.49.

More news about Kinross Gold.

6. Yamana Gold (AUY) – 7.42%

NYSE ended the session with Yamana Gold rising 7.42% to $4.42 on Wednesday while NYSE slid 0.63% to $16,844.15.

Volume

Today’s last reported volume for Yamana Gold is 13410900 which is 14.8% below its average volume of 15741300.

Yamana Gold’s last close was $4.11, 33.28% below its 52-week high of $6.16.

Yamana Gold’s Sales

Yamana Gold’s sales growth is 7% for the current quarter and 12.3% for the next.

Yamana Gold’s Revenue

Year-on-year quarterly revenue growth grew by 44.2%, now sitting on 1.76B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Yamana Gold’s stock is considered to be overbought (>=80).

Yamana Gold’s Stock Yearly Top and Bottom Value

Yamana Gold’s stock is valued at $4.42 at 16:32 EST, way below its 52-week high of $6.16 and way above its 52-week low of $3.82.

Yamana Gold’s Moving Average

Yamana Gold’s value is higher than its 50-day moving average of $4.14 and under its 200-day moving average of $4.45.

More news about Yamana Gold.

7. BP Prudhoe Bay Royalty Trust (BPT) – 7.25%

NYSE ended the session with BP Prudhoe Bay Royalty Trust jumping 7.25% to $6.19 on Wednesday, following the last session’s upward trend. NYSE dropped 0.63% to $16,844.15, after three consecutive sessions in a row of losses, on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for BP Prudhoe Bay Royalty Trust is 718861 which is 198.42% above its average volume of 240887.

BP Prudhoe Bay Royalty Trust’s last close was $5.77, 11.09% under its 52-week high of $6.49.

BP Prudhoe Bay Royalty Trust’s Stock Yearly Top and Bottom Value

BP Prudhoe Bay Royalty Trust’s stock is valued at $6.19 at 16:32 EST, below its 52-week high of $6.49 and way higher than its 52-week low of $2.71.

BP Prudhoe Bay Royalty Trust’s Moving Average

BP Prudhoe Bay Royalty Trust’s worth is way above its 50-day moving average of $4.20 and way higher than its 200-day moving average of $4.01.

More news about BP Prudhoe Bay Royalty Trust.

8. Merrimack Pharmaceuticals (MACK) – 7.25%

NASDAQ ended the session with Merrimack Pharmaceuticals rising 7.25% to $4.88 on Wednesday, following the last session’s downward trend. NASDAQ slid 1.15% to $14,340.25, following the last session’s downward trend on what was an all-around down trend trading session today.

Volume

Today’s last reported volume for Merrimack Pharmaceuticals is 152508 which is 507.96% above its average volume of 25085.

Merrimack Pharmaceuticals’s last close was $4.55, 51.85% under its 52-week high of $9.45.

Merrimack Pharmaceuticals’s Stock Yearly Top and Bottom Value

Merrimack Pharmaceuticals’s stock is valued at $4.88 at 16:32 EST, way under its 52-week high of $9.45 and way above its 52-week low of $3.83.

Merrimack Pharmaceuticals’s Moving Average

Merrimack Pharmaceuticals’s value is higher than its 50-day moving average of $4.45 and way below its 200-day moving average of $5.62.

More news about Merrimack Pharmaceuticals.

9. XP (XP) – 6.45%

NASDAQ ended the session with XP rising 6.45% to $29.06 on Wednesday while NASDAQ slid 1.15% to $14,340.25.

Volume

Today’s last reported volume for XP is 2914740 which is 25.13% below its average volume of 3893450.

XP’s last close was $27.30, 48.57% under its 52-week high of $53.08.

XP’s Sales

XP’s sales growth is 54.5% for the present quarter and 46.5% for the next. The company’s growth estimates for the current quarter and the next is 36.8% and 13%, respectively.

XP’s Revenue

Year-on-year quarterly revenue growth grew by 57.1%, now sitting on 10.14B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

XP’s stock is considered to be overbought (>=80).

XP’s Stock Yearly Top and Bottom Value

XP’s stock is valued at $29.06 at 16:32 EST, way below its 52-week high of $53.08 and above its 52-week low of $27.65.

XP’s Moving Average

XP’s worth is way below its 50-day moving average of $33.30 and way under its 200-day moving average of $40.20.

More news about XP.

10. Take-Two Interactive Software (TTWO) – 6.05%

NASDAQ ended the session with Take-Two Interactive Software jumping 6.05% to $163.36 on Wednesday, following the last session’s upward trend. NASDAQ fell 1.15% to $14,340.25, following the last session’s downward trend on what was an all-around negative trend trading session today.

Volume

Today’s last reported volume for Take-Two Interactive Software is 4717900 which is 190.72% above its average volume of 1622800.

Take-Two Interactive Software’s last close was $154.04, 28.32% below its 52-week high of $214.91.

The company’s growth estimates for the current quarter is a negative 33.5% and positive 4% for the next.

Take-Two Interactive Software’s Revenue

Year-on-year quarterly revenue growth grew by 2%, now sitting on 3.37B for the twelve trailing months.

Take-Two Interactive Software’s Stock Yearly Top and Bottom Value

Take-Two Interactive Software’s stock is valued at $163.36 at 16:32 EST, way under its 52-week high of $214.91 and way higher than its 52-week low of $144.58.

Take-Two Interactive Software’s Moving Average

Take-Two Interactive Software’s worth is under its 50-day moving average of $173.90 and under its 200-day moving average of $170.91.

More news about Take-Two Interactive Software.

Most Active Losers Today

1. NASDAQ TEST STOCK (ZWZZT) – -25%

NASDAQ ended the session with NASDAQ TEST STOCK dropping 25% to $15.00 on Wednesday, after five sequential sessions in a row of losses. NASDAQ slid 1.15% to $14,340.25, following the last session’s downward trend on what was an all-around down trend exchanging session today.

NASDAQ TEST STOCK’s last close was $21.00, 40% higher than its 52-week high of $15.00.

NASDAQ TEST STOCK’s Stock Yearly Top and Bottom Value

NASDAQ TEST STOCK’s stock is valued at $15.00 at 16:32 EST, below its 52-week low of $15.00.

More news about NASDAQ TEST STOCK.

2. NeuroMetrix (NURO) – -14.6%

NASDAQ ended the session with NeuroMetrix sliding 14.6% to $5.44 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ dropped 1.15% to $14,340.25, following the last session’s downward trend on what was an all-around negative trend trading session today.

Volume

Today’s last reported volume for NeuroMetrix is 2486810 which is 82.26% above its average volume of 1364380.

NeuroMetrix’s last close was $6.37, 83.56% under its 52-week high of $38.75.

NeuroMetrix’s Revenue

Year-on-year quarterly revenue growth declined by 0.8%, now sitting on 7.36M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

NeuroMetrix’s stock is considered to be oversold (<=20).

NeuroMetrix’s Stock Yearly Top and Bottom Value

NeuroMetrix’s stock is valued at $5.44 at 16:32 EST, way under its 52-week high of $38.75 and way higher than its 52-week low of $1.90.

NeuroMetrix’s Moving Average

NeuroMetrix’s worth is way below its 50-day moving average of $8.84 and way under its 200-day moving average of $6.85.

More news about NeuroMetrix.

3. Full House Resorts (FLL) – -9.06%

NASDAQ ended the session with Full House Resorts falling 9.06% to $8.83 on Wednesday, following the last session’s downward trend. NASDAQ dropped 1.15% to $14,340.25, following the last session’s downward trend on what was an all-around bearish trend exchanging session today.

Volume

Today’s last reported volume for Full House Resorts is 592189 which is 95.45% above its average volume of 302982.

Full House Resorts’s last close was $9.71, 20.28% below its 52-week high of $12.18.

Full House Resorts’s Sales

Full House Resorts’s sales growth is 9% for the current quarter and 14.1% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 71.4% and a negative 66.7%, respectively.

Full House Resorts’s Revenue

Year-on-year quarterly revenue growth grew by 36.8%, now sitting on 136.94M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Full House Resorts’s stock is considered to be overbought (>=80).

Full House Resorts’s Stock Yearly Top and Bottom Value

Full House Resorts’s stock is valued at $8.83 at 16:32 EST, way below its 52-week high of $12.18 and way above its 52-week low of $3.45.

Full House Resorts’s Moving Average

Full House Resorts’s worth is way below its 50-day moving average of $10.65 and under its 200-day moving average of $9.35.

More news about Full House Resorts.

4. Zentalis Pharmaceuticals (ZNTL) – -9%

NASDAQ ended the session with Zentalis Pharmaceuticals dropping 9% to $61.46 on Wednesday, following the last session’s downward trend. NASDAQ fell 1.15% to $14,340.25, following the last session’s downward trend on what was an all-around down trend trading session today.

Volume

Today’s last reported volume for Zentalis Pharmaceuticals is 329554 which is 32.3% above its average volume of 249090.

Zentalis Pharmaceuticals’s last close was $61.46, 29.51% below its 52-week high of $87.19.

The company’s growth estimates for the current quarter and the next is a negative 30.7% and a negative 20.2%, respectively.

Zentalis Pharmaceuticals’s Stock Yearly Top and Bottom Value

Zentalis Pharmaceuticals’s stock is valued at $61.46 at 16:32 EST, way below its 52-week high of $87.19 and way above its 52-week low of $34.48.

Zentalis Pharmaceuticals’s Moving Average

Zentalis Pharmaceuticals’s value is way below its 50-day moving average of $76.84 and below its 200-day moving average of $63.47.

More news about Zentalis Pharmaceuticals.

5. Y-mAbs Therapeutics (YMAB) – -8.75%

NASDAQ ended the session with Y-mAbs Therapeutics dropping 8.75% to $11.06 on Wednesday, after five consecutive sessions in a row of losses. NASDAQ dropped 1.15% to $14,340.25, following the last session’s downward trend on what was an all-around bearish trend exchanging session today.

Volume

Today’s last reported volume for Y-mAbs Therapeutics is 328087 which is 33.18% above its average volume of 246346.

Y-mAbs Therapeutics’s last close was $11.06, 78.19% under its 52-week high of $50.70.

Y-mAbs Therapeutics’s Sales

Y-mAbs Therapeutics’s sales growth is a negative 47.4% for the ongoing quarter and 158.2% for the next. The company’s growth estimates for the present quarter and the next is a negative 47.9% and a negative 181.3%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Y-mAbs Therapeutics’s stock is considered to be overbought (>=80).

Y-mAbs Therapeutics’s Stock Yearly Top and Bottom Value

Y-mAbs Therapeutics’s stock is valued at $11.06 at 16:32 EST, way under its 52-week high of $50.70 and above its 52-week low of $11.02.

Y-mAbs Therapeutics’s Moving Average

Y-mAbs Therapeutics’s value is way below its 50-day moving average of $17.37 and way below its 200-day moving average of $27.60.

More news about Y-mAbs Therapeutics.

6. Super Micro Computer (SMCI) – -8.71%

NASDAQ ended the session with Super Micro Computer sliding 8.71% to $42.15 on Wednesday, after three consecutive sessions in a row of gains. NASDAQ fell 1.15% to $14,340.25, following the last session’s downward trend on what was an all-around down trend exchanging session today.

Volume

Today’s last reported volume for Super Micro Computer is 401456 which is 71.61% above its average volume of 233922.

Super Micro Computer’s last close was $46.17, 2.06% below its 52-week high of $47.14.

The company’s growth estimates for the ongoing quarter and the next is a negative 32.7% and a negative 3.2%, respectively.

Super Micro Computer’s Revenue

Year-on-year quarterly revenue growth grew by 16%, now sitting on 3.38B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Super Micro Computer’s stock is considered to be oversold (<=20).

Super Micro Computer’s Stock Yearly Top and Bottom Value

Super Micro Computer’s stock is valued at $42.15 at 16:32 EST, way below its 52-week high of $47.14 and way above its 52-week low of $29.12.

Super Micro Computer’s Moving Average

Super Micro Computer’s value is above its 50-day moving average of $39.87 and way higher than its 200-day moving average of $37.35.

More news about Super Micro Computer.

7. Plug Power (PLUG) – -8.06%

NASDAQ ended the session with Plug Power sliding 8.06% to $20.99 on Wednesday, after four sequential sessions in a row of losses. NASDAQ fell 1.15% to $14,340.25, following the last session’s downward trend on what was an all-around negative trend trading session today.

Volume

Today’s last reported volume for Plug Power is 31059800 which is 48.45% above its average volume of 20921900.

Plug Power’s last close was $22.83, 69.76% under its 52-week high of $75.49.

Plug Power’s Sales

Plug Power’s sales growth is 12.2% for the current quarter and 62% for the next. The company’s growth estimates for the ongoing quarter and the next is 18.2% and 93.8%, respectively.

Plug Power’s Revenue

Year-on-year quarterly revenue growth grew by 83.2%, now sitting on -5.54M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Plug Power’s stock is considered to be overbought (>=80).

Plug Power’s Stock Yearly Top and Bottom Value

Plug Power’s stock is valued at $20.99 at 16:32 EST, way below its 52-week high of $75.49 and way above its 52-week low of $18.47.

Plug Power’s Moving Average

Plug Power’s worth is way below its 50-day moving average of $36.41 and way under its 200-day moving average of $31.07.

Previous days news about Plug Power

What this Plug Power analyst expects from hydrogen fuel cell company's jan. 19 update. According to Benzinga on Tuesday, 18 January, "The Plug Power Thesis: At its Jan. 19 business update call, Plug Power is likely to preannounce fourth-quarter revenues that are about 4% above the consensus estimate, Mariani said in a note.", "The Plug Power Analyst: Analyst Leo Mariani has an Overweight rating and a $40 price target for Plug Power shares."

More news about Plug Power.

8. Ameresco (AMRC) – -7.77%

NYSE ended the session with Ameresco sliding 7.77% to $52.69 on Wednesday while NYSE slid 0.63% to $16,844.15.

Volume

Today’s last reported volume for Ameresco is 568822 which is 70.28% above its average volume of 334049.

Ameresco’s last close was $52.69, 48.27% below its 52-week high of $101.86.

Ameresco’s Sales

Ameresco’s sales growth is 30.6% for the present quarter and 88% for the next. The company’s growth estimates for the current quarter is a negative 10.6% and positive 64% for the next.

Ameresco’s Revenue

Year-on-year quarterly revenue growth declined by 3.1%, now sitting on 1.11B for the twelve trailing months.

Ameresco’s Stock Yearly Top and Bottom Value

Ameresco’s stock is valued at $52.69 at 16:32 EST, way under its 52-week high of $101.86 and way above its 52-week low of $37.70.

Ameresco’s Moving Average

Ameresco’s worth is way below its 50-day moving average of $82.85 and way under its 200-day moving average of $66.81.

More news about Ameresco.

9. U.S. Bancorp (USB) – -7.75%

NYSE ended the session with U.S. Bancorp sliding 7.75% to $57.37 on Wednesday, after three consecutive sessions in a row of losses. NYSE fell 0.63% to $16,844.15, after three consecutive sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

Volume

Today’s last reported volume for U.S. Bancorp is 12427100 which is 137.57% above its average volume of 5230950.

U.S. Bancorp’s last close was $62.19, 1.3% below its 52-week high of $63.01.

U.S. Bancorp’s Sales

U.S. Bancorp’s sales growth is 1.4% for the current quarter and 1.3% for the next. The company’s growth estimates for the ongoing quarter and the next is 15.2% and 20%, respectively.

U.S. Bancorp’s Revenue

Year-on-year quarterly revenue growth grew by 46.5%, now sitting on 22.64B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

U.S. Bancorp’s stock is considered to be oversold (<=20).

U.S. Bancorp’s Stock Yearly Top and Bottom Value

U.S. Bancorp’s stock is valued at $57.37 at 16:32 EST, under its 52-week high of $63.01 and way above its 52-week low of $42.47.

U.S. Bancorp’s Moving Average

U.S. Bancorp’s value is under its 50-day moving average of $59.90 and below its 200-day moving average of $58.04.

More news about U.S. Bancorp.

10. Concord Medical Services Holdings Limited ADS (CCM) – -7.33%

NYSE ended the session with Concord Medical Services Holdings Limited ADS dropping 7.33% to $1.77 on Wednesday, following the last session’s downward trend. NYSE fell 0.63% to $16,844.15, after three sequential sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Volume

Today’s last reported volume for Concord Medical Services Holdings Limited ADS is 504 which is 84.73% below its average volume of 3301.

Concord Medical Services Holdings Limited ADS’s last close was $1.91, 59.36% under its 52-week high of $4.70.

Concord Medical Services Holdings Limited ADS’s Sales

Concord Medical Services Holdings Limited ADS’s sales growth is 20.7% for the current quarter and 20.7% for the next.

Concord Medical Services Holdings Limited ADS’s Revenue

Year-on-year quarterly revenue growth grew by 132.4%, now sitting on 332.89M for the twelve trailing months.

Concord Medical Services Holdings Limited ADS’s Stock Yearly Top and Bottom Value

Concord Medical Services Holdings Limited ADS’s stock is valued at $1.77 at 16:32 EST, under its 52-week low of $1.77.

Concord Medical Services Holdings Limited ADS’s Moving Average

Concord Medical Services Holdings Limited ADS’s worth is way under its 50-day moving average of $2.19 and way below its 200-day moving average of $2.81.

More news about Concord Medical Services Holdings Limited ADS.

Stay up to date with our winners and losers daily report